20 November 2026 | Friday | News
Image Source: Public Domain
PExA has filed a European patent application covering new methods for measuring and monitoring immune responses in the lower airways of the lungs. The application is based on research and method development conducted in collaboration with Professor Charlotte Thålin at Karolinska Institutet and Associate Professor Mikael Åberg at SciLifeLab, Uppsala University. The research findings were recently published in the scientific journal eBioMedicine, part of The Lancet Discovery Science.
The study demonstrates that antibody responses can differ between the upper and lower airways. Using PExA's technology, researchers can, for the first time, non-invasively monitor local antibody responses in the lungs' small airways over time and compare them with measurements from the upper airways. This opens new opportunities to investigate how immunity develops and changes following vaccination or infection, with potentially significant implications for future vaccine and drug development.
Part of a broader patent strategy
The patent application represents another step in PExA's strategy to build a broader intellectual property portfolio covering the company's technology and its applications. In recent years, PExA has also filed patent applications covering methods for RNA analysis, including microRNA and RNA fragmentomics, as well as biomarkers with potential applications in the early detection of lung cancer.
A common theme across these initiatives is how new scientific findings and analytical capabilities create opportunities for additional applications of PExA's research platform. By seeking patent protection for such applications, the company aims to strengthen its long-term position in research, diagnostic development and drug development.
We are seeing how new scientific findings continue to open up additional opportunities for our technology. Vaccine research is a particularly exciting area, where the ability to monitor immune responses directly in the lungs' small airways could be highly valuable for pharmaceutical companies developing and evaluating new vaccines. By also seeking patent protection for new methods and applications, we aim to position ourselves to capture part of the commercial value that these advances may generate. This is an important element of our long-term strategy to expand PExA's addressable market and build value around our technology, says Tomas Gustafsson, CEO of PExA.
The patent application, entitled "Non-Invasive Determination of Antibody Response in the Lower Airway", was filed with the European Patent Office (EPO) on August 21, 2026. The application is based on research and method development, the results of which were recently published in eBioMedicine, part of The Lancet Discovery Science.
© 2026 Biopharma Boardroom. All Rights Reserved.